Dr. Khan is an accomplished Director of Clinical Operations at NGM Biopharmaceuticals, where he leverages over 17 years of extensive leadership experience in managing global clinical trials across various phases, from first-in-human (FIH) studies to phase 4. In his current role, Dr. Khan is instrumental...
Dr. Khan is an accomplished Director of Clinical Operations at NGM Biopharmaceuticals, where he leverages over 17 years of extensive leadership experience in managing global clinical trials across various phases, from first-in-human (FIH) studies to phase 4. In his current role, Dr. Khan is instrumental in ensuring that clinical trials are meticulously resourced, managed, and executed within budgetary constraints while adhering to established timelines and quality standards. His strategic oversight encompasses all aspects of clinical trial management, where he actively directs and monitors the progress of assigned studies, ensuring alignment with regulatory requirements and organizational objectives.
One of Dr. Khan's key projects at NGM involves the development of innovative therapies targeting cancer, where he applies his profound expertise in clinical development and project management. His ability to lead cross-functional teams and foster collaboration among diverse stakeholders has been pivotal in driving project success. Dr. Khan is also responsible for the selection and management of Contract Research Organizations (CROs) and critical vendors, ensuring that partnerships are established with entities that share NGM's commitment to excellence in clinical research.
In addition to his operational responsibilities, Dr. Khan is dedicated to departmental leadership, focusing on the development of strategic goals and objectives that align with the company’s mission. His financial acumen and decision-making skills enable him to navigate complex challenges in the pharmaceutical industry effectively. As a mentor, he is passionate about nurturing the next generation of clinical operations professionals, sharing his insights and fostering a culture of continuous learning and improvement within his team. Through his unwavering commitment to advancing clinical science, Dr. Khan continues to make significant contributions to the field of biopharmaceuticals.
